NEW YORK (GenomeWeb) – Life sciences informatics company Benchling said today that it has closed a $14.5 million Series B round of venture capital. Benchmark led the round, with participation from Fidelity Investments' F-Prime Capital and previous investor Thrive Capital.

As as result of the investment, Benchmark General Partner Eric Vishria is joining the board of San Francisco-based Benchling. He touted the rise of biologics as a major factor in backing Benchling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.